| abstract |
The disclosure relates to fused pyrrole derivatives of formula (Ib) wherein A, Ar, R1, R2, R2' and R2'' and n are as defined in the specification, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medicaments for the therapeutic and/or prophylactic treatment of allergic, inflammatory or fibrotic diseases selected from allergy, asthma, peripheral arterial occlusive disease, critical limb ischemia, vulnerable atherosclerotic plaque patients, unstable angina, congestive heart failure, left ventricular hypertrophy, ischemia reperfusion injury, stroke, cardiomyopathy, restenosis, rheumatoid arthritis, diabetic nephropathy, irritable Bowel Disease, Crohns' disease, atherothrombosis or burns/ulcers in Diabetes/CLI. . . |